3-联苯羧酸乙酯 | 19926-50-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-联苯羧酸乙酯
• 英文名称: biphenyl-3-carboxylic acid ethyl ester
• 英文别名: ethyl [1,1'-biphenyl]-3-carboxylate；ethyl 3-phenylbenzoate；ethyl biphenyl-3-carboxylate
• CAS: 19926-50-2
• 化学式: C₁₅H₁₄O₂
• 分子量: 226.275
• InChiKey: UWJOIAKPUPVYPW-UHFFFAOYSA-N

物化性质

• 沸点：
  361.4±21.0 °C(Predicted)
• 密度：
  1.082±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2916399090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl biphenyl-3-carboxylate
Synonyms: Biphenyl-3-carboxylic acid ethyl ester

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl biphenyl-3-carboxylate
CAS number: 19926-50-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C15H14O2
Molecular weight: 226.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-联苯羧酸乙酯 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 18.0h， 以79.5%的产率得到3-苯基苯甲酸
  参考文献：
  名称：

  V1A和V2受体的非肽精氨酸加压素拮抗剂：2-苯基-4'-[（2,3,4,5-四氢-1H-1-苯并ze庚-1-基）羰基]苯甲腈衍生物的合成和药理特性。

  摘要：

  合成了一系列在结构上与4'-[（2,3,4,5-四氢-1H-1-苯并ze庚因-1-基）羰基]苯并ili啶有关的化合物，并证明它们具有精氨酸加压素（AVP）拮抗剂活性V1A和V2受体。将苯基或4-取代的苯基引入苯甲酰基部分的邻位导致结合亲和力和拮抗活性均增加。与2-甲基铅化合物相比，2-（4-甲基苯基）衍生物（1g）对V1A（8.6倍）和V2（38倍）受体均具有高拮抗活性，并且对口服活性（8.6倍）也较高（ 1a）。介绍了该系列的合成细节和药理特性。

  DOI：

  10.1248/cpb.45.1870
• 作为产物：
  描述：

  苯甲酸 在 盐酸 、 氢氧化钾 作用下， 生成 3-联苯羧酸乙酯
  参考文献：
  名称：

  Barth; Schreder, Monatshefte fur Chemie, 1882, vol. 3, p. 805

  摘要：

  DOI：

文献信息

• Synthesis of Pinacol Arylboronates from Aromatic Amines: A Metal-Free Transformation
  作者：Di Qiu、Liang Jin、Zhitong Zheng、He Meng、Fanyang Mo、Xi Wang、Yan Zhang、Jianbo Wang

  DOI：10.1021/jo3018878

  日期：2013.3.1

  A metal-free borylation process based on Sandmeyer-type transformation using arylamines derivatives as the substrates has been developed. Through optimization of the reaction conditions, this novel conversion can be successfully applied to a wide range of aromatic amines, affording borylation products in moderate to good yields. Various functionalized arylboronates, which are difficult to access by

  基于芳基胺衍生物作为底物的基于Sandmeyer型转化的无金属硼化工艺已得到开发。通过优化反应条件，这种新颖的转化方法可以成功地应用于各种芳族胺，从而以中等至良好的收率获得硼酸酯化产物。通过这种无金属的转化，可以容易地获得各种难以通过其他方法获得的官能化的芳基硼酸酯。此外，在不纯化硼酸酯化产物的情况下，Suzuki-Miyaura交叉偶联后即可进行这种转化，从而增强了该方法的实用性。已经提出了可能的涉及自由基物质的反应机理。
• 4-Alkyl-1,2,4-triazole-3-thione analogues as metallo-β-lactamase inhibitors
  作者：Laurent Gavara、Alice Legru、Federica Verdirosa、Laurent Sevaille、Lionel Nauton、Giuseppina Corsica、Paola Sandra Mercuri、Filomena Sannio、Georges Feller、Rémi Coulon、Filomena De Luca、Giulia Cerboni、Silvia Tanfoni、Giulia Chelini、Moreno Galleni、Jean-Denis Docquier、Jean-François Hernandez

  DOI：10.1016/j.bioorg.2021.105024

  日期：2021.8

  (BLs), including the highly worrying carbapenemases. Whereas inhibitors of these enzymes were recently marketed, they only target serine-carbapenemases (e.g. KPC-type), and no clinically useful inhibitor is available yet to neutralize the class of metallo-β-lactamases (MBLs). We are developing compounds based on the 1,2,4-triazole-3-thione scaffold, which binds to the di-zinc catalytic site of MBLs

  在革兰氏阴性菌中，对 β-内酰胺类抗生素产生耐药性的主要机制是产生一种或多种 β-内酰胺酶 (BLs)，包括令人担忧的碳青霉烯酶。尽管这些酶的抑制剂最近上市，但它们仅针对丝氨酸-碳青霉烯酶（例如 KPC 型），尚无临床上有用的抑制剂来中和金属-β-内酰胺酶 (MBL) 类。我们正在开发基于 1,2,4-三唑-3-硫酮支架的化合物，该支架以原始方式与 MBL 的二锌催化位点结合，我们之前报道了其产生广谱抑制剂的潜力。然而，到目前为止，在微生物测定中只能观察到适度的抗生素增强作用，需要进一步探索以改善外膜渗透。这里，我们合成并表征了一系列在杂环的 4 位具有不同官能化烷基链的化合物。我们发现在烷基链末端存在羧基会产生有效的 VIM 型酶抑制剂K i值在 μM 到亚 μM 范围内，并且该烷基链必须更长或等于丙基链。该结果证实了羧基官能团对 1,2,4-三唑-3-硫酮杂环的 4-取代基的重要性。如
• Derivatives of aminobenzoic and aminobiphenylcarboxylic acids useful as anti-cancer agents
  申请人：Schering Corporation

  公开号：US06228985B1

  公开（公告）日：2001-05-08

  The present invention provides compounds having the formula: wherein n is 0 or 1; R is —NH2 or wherein R1 and R2 are independently selected from the group consisting of H, alkyl, aralkyl, heteroaralkyl, carboxy, carboxyalkyl, and carbamoyl; Q is R3C(O)— or wherein R5 is selected from the group consisting of H, alkyl, aralkyl, heteroaralkyl, and carbamoylalkyl, and R3 and R4 are selected from the group consisting of H, alkyl, alkoxy, arylalkoxy, aralkyl, heteroaralkyl, and carbamoylalkyl; the Q—NH—(CH2)n— and the —C(O)R substituents of the compound of formula I are independently positioned ortho, meta, orpara relative to the carbon atoms that form the bond between the two phenyl groups to which said substituents are bound, with the proviso that said substituents are not both positioned ortho; and the Q—NH—(CH2)n and the —C(O)R substituents of the compound of formula II are positioned meta orpara to each other; or a biolabile ester thereof, or a pharmaceutically acceptable salt thereof. The compounds are useful for treating uPA- or uPAR-mediated disorders, e.g., tumor metastasis, tumor angiogenesis, restenosis, chronic inflammation, or corneal angiogenesis.

  本发明提供具有以下结构的化合物： 其中n为0或1； R为—NH2或 其中R1和R2分别选自H、烷基、芳基烷基、杂环芳基、羧基、羧基烷基和氨基甲酰基的群组； Q为R3C(O)—或 其中R5选自H、烷基、芳基烷基、杂环芳基和氨基甲酰基烷基的群组，R3和R4选自H、烷基、烷氧基、芳基烷氧基、芳基烷基、杂环芳基和氨基甲酰基烷基的群组； 公式I化合物的Q—NH—(CH2)n—和—C(O)R取代基独立地相对于形成两个苯基之间的碳原子定位于邻位、间位或对位，但前提是这些取代基不会同时定位于邻位；以及 公式II化合物的Q—NH—(CH2)n和—C(O)R取代基相对于彼此定位于间位或对位； 或其生物可降解酯，或其药学上可接受的盐。这些化合物可用于治疗uPA或uPAR介导的疾病，例如肿瘤转移、肿瘤血管生成、再狭窄、慢性炎症或角膜血管生成。
• Structure-activity relationship studies for the development of inhibitors of murine adipose triglyceride lipase (ATGL)
  作者：Nicole Mayer、Martina Schweiger、Elisabeth Fuchs、Anna K. Migglautsch、Carina Doler、Gernot F. Grabner、Matthias Romauch、Michaela-Christina Melcher、Rudolf Zechner、Robert Zimmermann、Rolf Breinbauer

  DOI：10.1016/j.bmc.2020.115610

  日期：2020.8

  non-alcoholic fatty liver disease (NAFLD) generalized in the term metabolic syndrome. Adipose triglyceride lipase (ATGL) is the initial enzyme in the hydrolysis of intracellular triacylglycerol (TG) stores, liberating fatty acids that are released from adipocytes into the circulation. Hence, ATGL-specific inhibitors have the potential to lower circulating FA concentrations, and counteract the development of insulin

  高血清脂肪酸（FA）水平与胰岛素抵抗的发展存在因果关系，胰岛素抵抗最终发展为2型糖尿病和在代谢综合征中普遍存在的非酒精性脂肪肝疾病（NAFLD）。甘油三酸酯脂肪酶（ATGL）是细胞内三酰基甘油（TG）储存液水解的初始酶，可释放从脂肪细胞释放到循环中的脂肪酸。因此，ATGL特异性抑制剂具有降低循环FA浓度并抵消胰岛素抵抗和NAFLD发生的潜力。在本文中，我们报告了鼠ATGL的小分子抑制剂的结构-活性关系（SAR）研究，该研究导致Atglistatin的发展。Atglistatin是鼠ATGL的特异性抑制剂，
• 4-Amino-1,2,4-triazole-3-thione-derived Schiff bases as metallo-β-lactamase inhibitors
  作者：Laurent Gavara、Laurent Sevaille、Filomena De Luca、Paola Mercuri、Carine Bebrone、Georges Feller、Alice Legru、Giulia Cerboni、Silvia Tanfoni、Damien Baud、Giuliano Cutolo、Benoît Bestgen、Giulia Chelini、Federica Verdirosa、Filomena Sannio、Cecilia Pozzi、Manuela Benvenuti、Karolina Kwapien、Marina Fischer、Katja Becker、Jean-Marie Frère、Stefano Mangani、Nohad Gresh、Dorothée Berthomieu、Moreno Galleni、Jean-Denis Docquier、Jean-François Hernandez

  DOI：10.1016/j.ejmech.2020.112720

  日期：2020.12

  potent, they represented a promising basis for the development of broad-spectrum MBL inhibitors. Here, we synthesized and characterized a large number of 4-amino-1,2,4-triazole-3-thione-derived Schiff bases. Compared to the previous series, the presence of an aryl moiety at position 4 afforded an average 10-fold increase in potency. Among 90 synthetic compounds, more than half inhibited at least one

  产生金属β-内酰胺酶（MBL）的革兰氏阴性菌对β-内酰胺抗生素的耐药性代表着重大的医学威胁，并且迫切需要开发临床上有用的抑制剂。我们先前报道了MBL催化位点中的5个取代的4-氨基/ H-1,2,4-三唑-3-硫酮化合物的原始结合模式。此外，我们表明，尽管具有中等效力，但它们代表了广谱MBL抑制剂开发的有希望的基础。在这里，我们合成和表征了大量的4-氨基-1,2,4-三唑-3-硫酮衍生的席夫碱。与先前的系列相比，在4位上存在芳基部分可使效力平均提高10倍。在90种合成化合物中，超过一半的化合物抑制了至少六个被测MBL（L1，VIM-4，VIM-2，NDM-1，IMP-1，K i的值在μM至亚μM范围内。几种是广谱抑制剂，也可以抑制临床上最相关的VIM-2和NDM-1。活性化合物通常在位置5处包含卤代，双环芳基或酚基部分，以及在邻苯甲酸，2,4-二羟基苯基，对苄氧基苯基或3-（m-苯甲酰基）-